John R Mascola Selected Research

Broadly Neutralizing Antibodies

1/2024	Antibodies targeting the fusion peptide on the HIV envelope provide protection to rhesus macaques against mucosal SHIV challenge.
10/2022	Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses.
1/2022	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
1/2022	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
1/2022	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2.
1/2022	First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody.
1/2022	Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
1/2022	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
1/2022	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
1/2021	A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John R Mascola Research Topics

Disease

147	Infections 01/2024 - 05/2002
28	Human Influenza (Influenza) 01/2023 - 12/2011
27	COVID-19 11/2023 - 06/2020
18	Viremia 10/2022 - 10/2003
16	Acquired Immunodeficiency Syndrome (AIDS) 07/2023 - 12/2003
14	HIV Infections (HIV Infection) 01/2022 - 11/2002
13	Virus Diseases (Viral Diseases) 02/2021 - 05/2002
7	Communicable Diseases (Infectious Diseases) 01/2022 - 07/2005
5	Neoplasms (Cancer) 07/2023 - 08/2015
5	Persistent Infection 01/2019 - 01/2015
4	Pneumonia (Pneumonitis) 09/2023 - 07/2015
4	Malaria 01/2022 - 01/2021
3	Headache (Headaches) 01/2023 - 10/2019
3	Zika Virus Infection 01/2020 - 01/2016
3	Ebola Hemorrhagic Fever 01/2017 - 04/2015
2	Equine Encephalomyelitis (Equine Encephalitis) 01/2022 - 01/2019
2	Edema (Dropsy) 02/2021 - 01/2021
2	Body Weight (Weight, Body) 01/2021 - 10/2017
2	Syphilis 01/2019 - 11/2003
2	Superinfection 01/2019 - 01/2018
1	Pain (Aches) 01/2024
1	Erythema 01/2024
1	Bronchiolitis 09/2023
1	Respiratory Tract Infections (Respiratory Tract Infection) 09/2023
1	Nausea 01/2023
1	Lymphopenia (Lymphocytopenia) 01/2023
1	Proteinuria 01/2023
1	Venezuelan Equine Encephalomyelitis 01/2022
1	Coronavirus Infections 01/2022
1	Neutropenia 01/2022
1	Flavivirus Infections 11/2021
1	Asymptomatic Infections 11/2021
1	Acute Lung Injury 10/2021
1	Severe Acute Respiratory Syndrome 10/2021
1	Weight Loss (Weight Reduction) 10/2021
1	Parasitemia 01/2021
1	Inflammation (Inflammations) 10/2020
1	Myalgia 10/2019

Drug/Important Bio-Agent (IBA)

101	VaccinesIBA 09/2023 - 11/2002
57	AntibodiesIBA 11/2023 - 05/2002
51	Broadly Neutralizing AntibodiesIBA 01/2024 - 11/2009
44	Neutralizing AntibodiesIBA 09/2023 - 05/2003
27	Monoclonal AntibodiesIBA 11/2023 - 10/2003
26	EpitopesIBA 09/2023 - 04/2005
19	Glycoproteins (Glycoprotein)IBA 09/2023 - 09/2009
17	Hemagglutinins (Hemagglutinin)IBA 01/2023 - 09/2015
17	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2003
13	Antiviral Agents (Antivirals)IBA 01/2021 - 11/2006
12	Proteins (Proteins, Gene)FDA Link 11/2023 - 11/2002
11	AntigensIBA 12/2021 - 11/2002
9	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022 - 12/2011
7	AIDS VaccinesIBA 07/2023 - 07/2009
7	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 04/2009
6	2019-nCoV Vaccine mRNA-1273IBA 11/2021 - 06/2020
5	RNA (Ribonucleic Acid)IBA 01/2022 - 05/2009
5	Bispecific AntibodiesIBA 10/2021 - 01/2017
5	Polysaccharides (Glycans)IBA 01/2020 - 01/2016
4	Peptides (Polypeptides)IBA 04/2022 - 01/2013
4	Immunoglobulin G (IgG)IBA 01/2022 - 01/2013
3	Ferritins (Ferritin)IBA 01/2023 - 11/2018
3	Indicators and Reagents (Reagents)IBA 10/2017 - 08/2005
3	DNA VaccinesIBA 09/2015 - 07/2005
3	Viral RNAIBA 07/2011 - 11/2003
2	Messenger RNA (mRNA)IBA 08/2023 - 12/2021
2	COVID-19 VaccinesIBA 08/2023 - 06/2020
2	Virus-Like Particle VaccinesIBA 01/2023 - 01/2019
2	NanovaccinesIBA 01/2023 - 01/2021
2	DH1047IBA 01/2022 - 04/2021
2	aluminum sulfate (alum)IBA 01/2022 - 10/2021
2	Antimalarials (Antimalarial Agents)IBA 01/2022 - 01/2021
2	Biological Warfare AgentsIBA 01/2022 - 02/2015
2	bamlanivimabIBA 12/2021 - 10/2020
2	Blocking AntibodiesIBA 02/2021 - 01/2021
2	CytokinesIBA 02/2021 - 01/2021
2	Fc Receptors (Fc Receptor)IBA 02/2021 - 01/2021
2	Immunoglobulin A (IgA)IBA 11/2019 - 01/2013
2	peptide AIBA 01/2018 - 01/2018
2	Cell Surface ReceptorsIBA 10/2016 - 07/2014
2	Inactivated VaccinesIBA 09/2015 - 08/2013
2	env Gene ProductsIBA 04/2015 - 06/2006
2	GP 140IBA 07/2011 - 04/2009
2	ImmunosorbentsIBA 07/2008 - 11/2002
2	EnzymesIBA 07/2008 - 11/2002
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023
1	Alanine Transaminase (SGPT)IBA 01/2023
1	Viral ProteinsIBA 01/2022
1	Vorinostat FDA Link 01/2022
1	mRNA VaccinesIBA 12/2021
1	Protein Subunit VaccinesIBA 10/2021
1	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 03/2021
1	CIS43LSIBA 01/2021
1	IgG Receptors (Fc gamma RI)IBA 01/2020

Therapy/Procedure

14	Therapeutics 01/2022 - 02/2004
3	Aftercare (After-Treatment) 01/2022 - 08/2015
2	Injections 01/2024 - 11/2021
2	Intravenous Administration 01/2023 - 10/2019
2	Highly Active Antiretroviral Therapy (HAART) 01/2016 - 10/2015
1	Transcutaneous Electric Nerve Stimulation (TENS) 09/2023
1	Drug Therapy (Chemotherapy) 01/2022
1	Intramuscular Injections 11/2021